Dr. Robert F. Manges, MD

Dr. Manges practices at Parkview Regional Medical Center in Fort Wayne, Indiana, part of Parkview Health System.

Dr. Manges' NPI, 1508835174, was assigned on March 16, 2006. Dr. Manges graduated from Indiana University School of Medicine in 1988. Dr. Manges holds Indiana license 01037708A.

Dr. Manges' primary practice is Parkview Regional Medical Center, at 11109 Parkview Plaza Drive, Fort Wayne, IN 46845 in Allen County. The practice phone is (260) 266-1195.

Dr. Manges' primary practice is Parkview Regional Medical Center in Fort Wayne, Indiana, part of Parkview Health System. Dr. Manges is also affiliated with Parkview Whitley Hospital. The medical group on file is Parkview Physicians Group. Dmand AI also links Dr. Manges to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Manges practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Manges' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Manges is licensed in Indiana.

CMS data shows 978 Medicare services from Dr. Manges across 7 procedure codes in 2024, for 371 Medicare patients. Medicare paid $59,608 for them.

CMS counts 371 Medicare patients who saw Dr. Manges in 2024. The largest group is 65 to 74, with 171 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 12% are also on Medicaid. Their average risk score is 2.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Manges' median patient age at 73, with 46% women.

In 2024, Dr. Manges wrote 9,761 Medicare Part D claims for 2,421 patients. 89% of them were for generic drugs. CMS names the drug for 9,488 of them, across 47 drugs with 11 or more claims each, at $12,519,206 in total drug cost. In 2023, CMS named 9,210 claims across 41 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Manges for performance year 2024, reported as part of a group. Dr. Manges accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Manges as offering telehealth.

Dmand AI links 5 papers to Dr. Manges, published from 2013 to 2021. 2015 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Dexamethasone and Multiple Myeloma. Dr. Manges' most frequent co-authors are Sundar Jagannath, MD, Suprith Badarinath, MD and Ashraf Zarif Badros, MD.

Dmand AI links Dr. Manges to 6 clinical trials, 3 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Burkitt Lymphoma, GATA2 Deficiency and Lymphoma, Follicular. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 1,500 general payments to Dr. Manges from 83 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 66% of the total. Amgen Inc. paid the most, $7,385.

Dr. Manges graduated from Indiana University School of Medicine in 1988.